April W. Armstrong, MD, MPH; Peter A. Lio, MD; Linda Stein Gold, MD
This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.
April W. Armstrong, MD, MPH
Associate Dean, Clinical Research
Professor of Dermatology
Keck School of Medicine
University of Southern California
Los Angeles, California
Peter A. Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Feinberg School of Medicine
Director, Chicago Integrative Eczema Center
Founding Partner, Medical Dermatology Associates of Chicago
Linda Stein Gold, MD
Director of Dermatology Clinical Research
Henry Ford Health System
Division Head of Dermatology
Henry Ford Health System
West Bloomfield, Michigan
The educational design of this activity addresses the needs of dermatologists, allergists/clinical immunologists, and other clinicians who treat patients with severe atopic dermatitis.
Statement of Need/Program Overview
Atopic dermatitis is a common, chronic, inflammatory disease that manifests primarily in the skin, although research has uncovered potentially deleterious effects in other organ systems throughout the body.1,2 The disease-related physical and biopsychosocial burdens of this condition can have a substantial effect on patient and parent/caregiver quality of life.3,4 A better understanding of disease etiology has supported the development of new approaches to disease characterization and targeted therapies.5,6 As a result, the first biologic therapy is now FDA-approved to treat adolescent and adult patients 12 years and older, with moderate-to-severe disease.7,8 In this Clinical Issues™ program, an expert faculty panel will discuss and debate the pathophysiologic underpinnings of atopic dermatitis, considerations related to comprehensively evaluating patients, and recommended therapeutic strategies for adolescents and adults with moderate-to-severe disease. With novel therapies emerging for patients with difficult-to-treat atopic dermatitis, attendees will benefit from updates on the newest clinical trial data, evolving treatment guidelines, and practical recommendations that may be applied to daily clinical decision-making.9,10 Participants will leave this dynamic and engaging program well-equipped to translate the latest information and new perspectives on disease management into next-day practice.
- Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16.
- Brunner PM, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Invest Dermatol. 2017;137(1):18-25.
- Carroll CL, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192-199.
- Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30.
- Mansouri Y, Guttman-Yassky E. Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med. 2015;4(5):858-873.
- Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50.
- Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
- Simpson EL, et al. Dupilumab efficacy and safety in adolescents with moderate-to-severe atopic dermatitis: results from a multicenter, randomized, placebo-controlled, double-blind, parallel-group, phase 3 study. Presented at the 27th EADV Congress. September 12-16, 2018; Paris, France. Poster #4640.
- Renert-Yuval Y, Guttman-Yassky E. What’s new in atopic dermatitis. Dermatol Clin. 2019;37(2):205-213.
- Ariëns LFM, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. Ther Adv Chronic Dis. 2018;9(9):159-170.
Upon completion of this activity, participants will be better able to do the following:
- Describe the pathophysiologic mechanisms and risk factors that contribute to atopic dermatitis development and persistence, with a focus on specific targets of current and emerging systemic treatments
- Assess patients with atopic dermatitis over time for uncontrolled symptoms, sleep disturbances, comorbid conditions, and treatment responses
- Describe the mechanistic rationales and clinical evidence for current and emerging biologic therapies in the treatment of moderate-to-severe atopic dermatitis
- Individualize long-term therapeutic regimens for moderate-to-severe atopic dermatitis to prevent exacerbations, manage comorbidities, maximize health-related quality of life, and minimize treatment-related side effects
- Communicate with patients and caregivers to improve their understanding of atopic dermatitis and the importance of treatment adherence and to promote shared decision-making
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 70% or better on the posttest and complete the program evaluation.
Microsoft Windows 2000 SE or above.
Flash Player Plugin (v220.127.116.11 or greater)
Internet Explorer (v5.5 or greater), or Firefox
Adobe Acrobat Reader*
MAC OS 10.2.8
Flash Player Plugin (v18.104.22.168 or greater)
Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh.
Fee Information & Refund Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
April W. Armstrong, MD, MPH: Consultant/Advisor: Abbvie Inc., Bristol-Myers Squibb, Dermavant Sciences, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., LEO Pharma Inc., Modernizing Medicine, Inc., Novartis Corporation, Ortho Dermatologics, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Science 37, Inc. Research Grant: Abbvie Inc., Bristol-Myers Squibb, Dermira, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Kyowa Hakko Kirin Co., Ltd., LEO Pharma Inc., Novartis Corporation, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, UCB Biopharma
Peter A. Lio, MD: Consultant/Independent Contractor: Abbvie Inc., Altus Labs, LLC, AOBiome, Dermavant Sciences, Inc., Eli Lilly and Company, Galderma Laboratories, L.P., IntraDerm Pharmaceuticals, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., La Roche-Posay, Menlo, Micreos, Pfizer Inc., Pierre Fabre Laboratories, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Theraplex, UCB Biopharma, Unilever. Grant/Research Support: Abbvie Inc., AOBiome, The Atopic Dermatitis Foundation, Regeneron Pharmaceuticals, Inc. Honoraria: Abbvie Inc., Altus Labs, LLC, AOBiome, Dermavant Sciences, Inc., Eli Lilly and Company, Galderma Laboratories, L.P., IntraDerm Pharmaceuticals, Johnson & Johnson, Kiniksa Pharmaceuticals, Ltd., La Roche-Posay, Menlo Therapeutics Inc., Micreos BV, Pfizer Inc., Pierre Fabre Laboratories, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Theraplex, UCB Biopharma, Unilever. Speakers Bureau: La Roche-Posay, Pfizer Inc., Pierre Fabre Laboratories, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme. Stock Shareholder: Altus Labs, LLC, Franklin Bioscience, Micreos BV, Syncere Skin Systems, Theraplex
Linda Stein Gold, MD: Consultant/Independent Contractor: Abbvie Inc., Dermavant Sciences, Inc., LEO Pharma Inc., Valeant Phamaceuticals International, Inc. Grant/Research Support: Abbvie Inc., Dermavant Sciences, Inc., LEO Pharma Inc., Valeant Phamaceuticals International, Inc. Speakers Bureau: LEO Pharma Inc., Pfizer Inc., Valeant Pharmaceuticals International, Inc.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lindsay Borvansky: Nothing to disclose.
Andrea Funk: Nothing to disclose
Liddy Knight: Nothing to disclose
Ashley Cann: Nothing to disclose
Stacey Ullman, MHS: Nothing to disclose
Rose O'Connor, PhD, CHCP: Nothing to disclose
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 1.00
credit type CME